Six biotechs crowd in­to Nas­daq, rais­ing $568M as the IPO par­ty con­tin­ues to lure com­pa­nies to Wall Street

Usu­al­ly biotech IPOs come one or maybe two at a time. To­day, we have 5 si­mul­ta­ne­ous­ly test­ing in­vestors’ ap­petite for risky com­pa­nies that will ei­ther re­ward them hand­some­ly over the long haul or … well, not. And I’m adding a 6th, from Ei­dos Ther­a­peu­tics, that got a jump on the gang of 5 and an­nounced their pric­ing late Tues­day.

Add it all up and the 6 are ben­e­fit­ing from a to­tal raise of $568 mil­lion, gen­er­al­ly pric­ing shares in the mid­dle of the range — just the lat­est wind­fall to help fu­el the R&D work of a steady stream of play­ers who have been mak­ing the switch to the pub­lic mar­kets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER